^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PT217

    i
    Other names: PT217, PT-217, PT 217
    Company:
    Phanes Therap
    Drug class:
    CD47 inhibitor, DLL3 inhibitor
    Related drugs:
    1m
    A Study of PT217 in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) (clinicaltrials.gov)
    P1/2, N=203, Recruiting, Phanes Therapeutics | N=61 --> 203 | Trial completion date: Jun 2025 --> Aug 2028 | Trial primary completion date: Jan 2025 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    Tecentriq (atezolizumab) • carboplatin • paclitaxel • etoposide IV • PT217
    7ms
    A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) (clinicaltrials.gov)
    P1/2, N=61, Recruiting, Phanes Therapeutics | Phase classification: P1 --> P1/2
    Phase classification
    |
    EGFR (Epidermal growth factor receptor) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    PT217
    over1year
    A Phase 1 Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3 (clinicaltrials.gov)
    P1, N=58, Recruiting, Phanes Therapeutics | Not yet recruiting --> Recruiting | Initiation date: Jan 2023 --> Jun 2023
    Enrollment open • Trial initiation date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    PT217
    2years
    A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3 (clinicaltrials.gov)
    P1, N=58, Not yet recruiting, Phanes Therapeutics
    New P1 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    PT217
    almost3years
    PT217, an anti-DLL3/anti-CD47 bispecific antibody, exhibits anti-tumor activity through novel mechanisms of action (AACR 2022)
    Furthermore, PT217 exhibits regular mAb-like manufacturability in process development and CMC. We expect to initiate a phase 1 trial to target SCLC in the first half of 2022.
    IO biomarker
    |
    CD47 (CD47 Molecule) • DLL3 (Delta Like Canonical Notch Ligand 3) • SIRPA (Signal Regulatory Protein Alpha)
    |
    DLL3 expression
    |
    PT217